ReviewInternational journal of endocrinology2014
Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System.
Review in International journal of endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Functional pituitary adenoma imaging.Reviews in endocrine & metabolic disorders · 2026Review
- The value of targeting CXCR4 withEuropean journal of nuclear medicine and molecular imaging · 2026Article
- The value ofHypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- New Sparks and Spots: Molecular Imaging with Positron Emission Tomography Will Change Management of Cushing's Disease.Endocrinology and metabolism (Seoul, Korea) · 2026Review
- Age-dependent effects of chronic traumatic and social isolation stress on mice social behavior.Neurobiology of stress · 2026Article
- Advances in Endocrine Tumor PET Imaging Targeting CXCR4 and GLP-1.Seminars in nuclear medicine · 2025Review
- Endoscopic endonasal surgery using indocyanine green fluorescence endoscope for Cushing's disease caused by mixed intrasellar gangliocytoma and adrenocorticotropin adenoma: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Malignant melanoma with pituitary metastasis: A case report and literature review.Frontiers in endocrinology · 2025Review
- Promising bioactive compounds from the marine environment and their potential effects on various diseases.Journal, genetic engineering & biotechnology · 2022Review
- Large Scale Molecular Studies of Pituitary Neuroendocrine Tumors: Novel Markers, Mechanisms and Translational Perspectives.Cancers · 2021Review
- Up-regulation of sex-determining region Y-box 9 (SOX9) in growth hormone-secreting pituitary adenomas.BMC endocrine disorders · 2021Article
- Bioactive Compounds from Marine Heterobranchs.Marine drugs · 2020Review
- Molecular alterations in non-functioning pituitary adenomas.Cancer biomarkers : section A of Disease markers · 2020Article
- SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor GrowthFrontiers in endocrinology · 2020Article
- Experimental Evidence and Clinical Implications of Pituitary Adenoma Stem Cells.Frontiers in endocrinology · 2020Review
- Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms.International journal of molecular sciences · 2019Review
- High expression of SDF-1 and VEGF is associated with poor prognosis in patients with synovial sarcomas.Experimental and therapeutic medicine · 2018Article
- CXCR7 regulates breast tumor metastasis and angiogenesis in vivo and in vitro.Molecular medicine reports · 2018Article
- Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas.Molecular neurobiology · 2017Article
- An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs.Molecules (Basel, Switzerland) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemokines are chemotactic regulators of immune surveillance in physiological and pathological conditions such as inflammation, infection, and cancer. Several chemokines and cognate receptors are constitutively expressed in the central nervous system, not only in glial and endothelial cells but also in neurons, controlling neurogenesis, neurite outgrowth, and axonal guidance during development. In particular, the chemokine CXCL12 and its receptors, CXCR4 and CXCR7, form a functional network that controls plasticity in different brain areas, influencing neurotransmission, neuromodulation, and cell migration, and the dysregulation of this chemokinergic axis is involved in several neurodegenerative, neuroinflammatory, and malignant diseases. CXCR4 primarily mediates the transduction of proliferative signals, while CXCR7 seems to be mainly responsible for scavenging CXCL12. Importantly, the multiple intracellular signalling generated by CXCL12 interaction with its receptors influences hypothalamic modulation of neuroendocrine functions, although a direct modulation of pituitary functioning via autocrine/paracrine mechanisms was also reported. Both CXCL12 and CXCR4 are constitutively overexpressed in pituitary adenomas and their signalling induces cell survival and proliferation, as well as hormonal hypersecretion. In this review we focus on the physiological and pathological functions of immune-related cyto- and chemokines, mainly focusing on the CXCL12/CXCR4-7 axis, and their role in pituitary tumorigenesis. Accordingly, we discuss the potential targeting of CXCR4 as novel pharmacological approach for pituitary adenomas.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.